Skip to main content

Top U.S. automakers reported another month of rises in sales of sport-utility vehicles and pickup trucks on Thursday as American consumers continued to shun sedans and hatchbacks.

The No. 2 U.S. producer, Ford Motor Co., reported a 6.7-per-cent rise in SUV sales to 67,554 units in October, while smaller rival Fiat Chrysler Automobiles NV saw overall sales rise 16 per cent on higher demand for its Jeep and Ram vehicles.

U.S. car sales, which dropped 2 per cent last year from a record high of 17.55 million in 2016, are expected to fall further in 2018, hurt by rising interest rates and the return of more late-model used cars to dealer lots.

Story continues below advertisement

But automakers have benefited from a shift by U.S. consumers away from traditional passenger cars toward larger, more comfortable SUVs and trucks, which tend to be more profitable for producers.

Sport-utility vehicles contributed about 35 per cent of Ford’s total U.S. sales volumes in October, up from 31.6 per cent a year ago.

Ford, which is also gradually phasing out production of most passenger cars in the United States, said total sales fell 3.9 per cent to 192,616 vehicles, hurt by lower passenger car demand.

Toyota Motor Corp. of Japan separately said its U.S. sales rose about 1.4 per cent to 191,102 units, due to increased demand for its Highlander and Tacoma SUVs.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies